{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:36:13Z","timestamp":1790361373758,"version":"4.1.0"},"reference-count":73,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003516","name":"Winn Feline Foundation","doi-asserted-by":"publisher","award":["2019_027"],"award-info":[{"award-number":["2019_027"]}],"id":[{"id":"10.13039\/100003516","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Animals"],"abstract":"<jats:p>The pharmacokinetic profile of mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections (such as feline infectious peritonitis) or feline calicivirus infections. Mefloquine was administered at 62.5 mg orally to seven clinically healthy cats twice weekly for four doses and mefloquine plasma concentrations over 336 h were measured using high pressure liquid chromatography (HPLC). The peak plasma concentration (Cmax) after a single oral dose of mefloquine was 2.71 ug\/mL and time to reach Cmax (Tmax) was 15 h. The elimination half-life was 224 h. The plasma concentration reached a higher level at 4.06 ug\/mL when mefloquine was administered with food. Adverse effects of dosing included vomiting following administration without food in some cats. Mild increases in serum symmetric dimethylarginine (SDMA), but not creatinine, concentrations were observed. Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus infections in cats.<\/jats:p>","DOI":"10.3390\/ani10061000","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T06:34:16Z","timestamp":1591684456000},"page":"1000","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP)"],"prefix":"10.3390","volume":"10","author":[{"given":"Jane","family":"Yu","sequence":"first","affiliation":[{"name":"Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kimble","sequence":"additional","affiliation":[{"name":"Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0003-6930","authenticated-orcid":false,"given":"Jacqueline M.","family":"Norris","sequence":"additional","affiliation":[{"name":"Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merran","family":"Govendir","sequence":"additional","affiliation":[{"name":"Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Felten, S., and Hartmann, K. (2019). Diagnosis of Feline Infectious Peritonitis: A Review of the Current Literature. Viruses, 11.","DOI":"10.3390\/v11111068"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jfms.2008.02.006","article-title":"Pathogenesis of feline enteric coronavirus infection","volume":"10","author":"Pedersen","year":"2008","journal-title":"J. Feline Med. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jfms.2009.05.008","article-title":"Feline infectious peritonitis. ABCD guidelines on prevention and management","volume":"11","author":"Addie","year":"2009","journal-title":"J. Feline Med. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jfms.2008.09.008","article-title":"A review of feline infectious peritonitis virus infection: 1963\u20132008","volume":"11","author":"Pedersen","year":"2009","journal-title":"J. Feline Med. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tvjl.2014.04.016","article-title":"An update on feline infectious peritonitis: Diagnostics and therapeutics","volume":"201","author":"Pedersen","year":"2014","journal-title":"Vet. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jfms.2010.09.014","article-title":"Clinicopathological findings and disease staging of feline infectious peritonitis: 51 cases from 2003 to 2009 in Taiwan","volume":"13","author":"Tsai","year":"2011","journal-title":"J. Feline Med. Surg."},{"key":"ref_7","first-page":"53","article-title":"Prolonged survival of a cat diagnosed with feline infectious peritonitis by immunohistochemistry","volume":"56","author":"Hugo","year":"2015","journal-title":"Can. Vet. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jfms.2003.08.011","article-title":"Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis","volume":"6","author":"Ishida","year":"2004","journal-title":"J. Feline Med. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kim, Y., Liu, H., Galasiti Kankanamalage, A.C., Weerasekara, S., Hua, D.H., Groutas, W.C., Chang, K.O., and Pedersen, N.C. (2016). Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005531"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2012.11.005","article-title":"Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease","volume":"97","author":"Kim","year":"2013","journal-title":"Antiviral Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vetmic.2018.04.026","article-title":"The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies","volume":"219","author":"Murphy","year":"2018","journal-title":"Vet. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1098612X17729626","article-title":"Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis","volume":"20","author":"Pedersen","year":"2018","journal-title":"J. Feline Med. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1098612X19825701","article-title":"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis","volume":"21","author":"Pedersen","year":"2019","journal-title":"J. Feline Med. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2010.06.010","article-title":"Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus","volume":"88","author":"Hsieh","year":"2010","journal-title":"Antiviral Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","article-title":"Antiviral drug resistance: Mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jfms.2009.05.004","article-title":"ABCD guidelines on prevention and management","volume":"11","author":"Radford","year":"2009","journal-title":"J. Feline Med. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.vetmic.2014.10.030","article-title":"Identification and characterisation of small molecule inhibitors of feline coronavirus replication","volume":"174","author":"McDonagh","year":"2014","journal-title":"Vet. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Izes, A.M., Kimble, B., Norris, J.M., and Govendir, M. (2020). In vitro hepatic metabolism of mefloquine using microsomes from cats, dogs and the common brush-tailed possum (Trichosurus vulpecula). PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230975"},{"key":"ref_19","unstructured":"Izes, A.M. (2019). Comparative Studies of in Vitro Hepatic Metabolism of Mefloquine by Feline Microsomes and Those of Other Selected Species. [Ph.D. Thesis, The University of Sydney]."},{"key":"ref_20","first-page":"238","article-title":"Kinetic studies of mefloquine and of one of its metabolites, Ro 21-5104, in the dog and in man","volume":"37","author":"Schwartz","year":"1980","journal-title":"Acta. Trop."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1647\/2003-008","article-title":"Intracellular Hematozoa of Raptors: A Review and Update","volume":"18","author":"Remple","year":"2004","journal-title":"J. Avian Med. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/03079457.2016.1149145","article-title":"Malaria in penguins\u2014Current perceptions","volume":"45","author":"Grilo","year":"2016","journal-title":"Avian Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00415-019-09629-x","article-title":"Successful treatment of non-HIV progressive multifocal leukoencephalopathy: Case report and literature review","volume":"267","author":"Hamaguchi","year":"2020","journal-title":"J. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.4103\/neuroindia.NI_535_16","article-title":"Progressive multifocal leukoencephalopathy in a 44-year old male with idiopathic CD4+ T-lymphocytopenia treated with mirtazapine and mefloquine","volume":"65","author":"Nambirajan","year":"2017","journal-title":"Neurol. India"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.vetmic.2015.02.007","article-title":"Antiviral effect of mefloquine on feline calicivirus in vitro","volume":"176","author":"McDonagh","year":"2015","journal-title":"Vet. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.antiviral.2016.11.015","article-title":"Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus","volume":"137","author":"Balasubramanian","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","article-title":"Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model","volume":"133","author":"Fan","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/AAC.01614-08","article-title":"Identification and characterization of mefloquine efficacy against JC virus in vitro","volume":"53","author":"Brickelmaier","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1124\/jpet.105.086272","article-title":"In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine","volume":"314","author":"Owen","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2165\/00003495-199345030-00009","article-title":"Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy","volume":"45","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2165\/00003088-199019040-00002","article-title":"Clinical pharmacokinetics of mefloquine","volume":"19","author":"Karbwang","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt1979263372","article-title":"Kinetics of a new antimalarial, mefloquine","volume":"26","author":"Desjardins","year":"1979","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1472-8206.1994.tb00830.x","article-title":"Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria","volume":"8","author":"Karbwang","year":"1994","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF03190836","article-title":"Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria","volume":"14","author":"Juma","year":"1989","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_35","unstructured":"Tan, K.R., Arguin, P.M., and Arguin, T. (2020, April 21). Travel Related Infectious Disease, Centers for Disease Control and PRevention. CDC Yellow Book 2020: Health Information for International Travel, Available online: https:\/\/www.cbc.gov\/malaria\/travelers\/drugs.html."},{"key":"ref_36","unstructured":"(2020, April 21). Centers for Disease Control and Prevention, Malaria, how to Choose a Drug to Prevent Malaria, Available online: https:\/\/www.cdc.gov\/malaria\/travelers\/drugs.html."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00003088-198510030-00001","article-title":"Clinical pharmacokinetics of antimalarial drugs","volume":"10","author":"White","year":"1985","journal-title":"Clin. Pharmacokinet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s002280050351","article-title":"Food increases the bioavailability of mefloquine","volume":"53","author":"Crevoisier","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/2229-5070.175081","article-title":"Antimalarial drug resistance: An overview","volume":"6","author":"Antony","year":"2016","journal-title":"Trop. Parasitol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2013.04.016","article-title":"Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo","volume":"99","author":"Takano","year":"2013","journal-title":"Antiviral Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Coronavirus Pandemic-Therapy and Vaccines. Biomedicines, 8.","DOI":"10.3390\/biomedicines8050109"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Takano, T., Satoh, K., Doki, T., Tanabe, T., and Hohdatsu, T. (2020). Antiviral Effects of Hydroxychloroquine and Type I Interferon on In Vitro Fatal Feline Coronavirus Infection. Viruses, 12.","DOI":"10.3390\/v12050576"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jama.1991.03460030067030","article-title":"Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine. Need for a better dosing regimen","volume":"265","author":"Lobel","year":"1991","journal-title":"JAMA"},{"key":"ref_44","first-page":"913","article-title":"Single-dose treatment of falciparum malaria with mefloquine: Field studies with different doses in semi-immune adults and children in Burma","volume":"60","author":"Tin","year":"1982","journal-title":"Bull. World Health Organ."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/0140-6736(93)93058-9","article-title":"Long-term malaria prophylaxis with weekly mefloquine","volume":"341","author":"Lobel","year":"1993","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.bjp.0703638","article-title":"The antimalarial agent mefloquine inhibits ATP-sensitive K-channels","volume":"131","author":"Gribble","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tmaid.2014.10.021","article-title":"Acute and long-term psychiatric side effects of mefloquine: A follow-up on Danish adverse event reports","volume":"13","author":"Ringqvist","year":"2015","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_48","first-page":"224","article-title":"Psychiatric side effects of mefloquine: Applications to forensic psychiatry","volume":"41","author":"Ritchie","year":"2013","journal-title":"J. Am. Acad. Psychiatry Law"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lee, S.J., Ter Kuile, F.O., Price, R.N., Luxemburger, C., and Nosten, F. (2017). Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0168780"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2230.1999.00471.x","article-title":"Dermatological adverse effects with the antimalarial drug mefloquine: A review of 74 published case reports","volume":"24","author":"Smith","year":"1999","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/clinids\/18.2.263","article-title":"Aplastic anemia during malarial prophylaxis with mefloquine","volume":"18","author":"Stracher","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","first-page":"563","article-title":"Treatment of Plasmodium falciparum malaria with mefloquine alone or in combination with i.v. quinine at the Department of Communicable and Tropical Diseases, Rigshospitalet, Copenhagen 1982\u20131988","volume":"37","author":"Magnussen","year":"1990","journal-title":"Dan. Med. Bull."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/03602530902722679","article-title":"Pharmacokinetics and drug metabolism in the elderly","volume":"41","author":"Klotz","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF03190160","article-title":"Pharmacokinetics of mefloquine in children aged 6 to 24 months","volume":"17","author":"Singhasivanon","year":"1992","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bjid.2016.07.005","article-title":"Patient age does not affect mefloquine concentrations in erythrocytes and plasma during the acute phase of falciparum malaria","volume":"20","author":"Vieira","year":"2016","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00542191","article-title":"The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects","volume":"32","author":"Karbwang","year":"1987","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2125.1987.tb03133.x","article-title":"Studies of mefloquine bioavailability and kinetics using a stable isotope technique: A comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers","volume":"24","author":"Looareesuwan","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0024-3205(00)00546-4","article-title":"Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes","volume":"66","author":"Fontaine","year":"2000","journal-title":"Life Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2885.2007.00902.x","article-title":"Characterization of cytochrome P450-mediated drug metabolism in cats","volume":"30","author":"Shah","year":"2007","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jac\/dku430","article-title":"Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria","volume":"70","author":"Reuter","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1016\/j.bmc.2008.01.053","article-title":"Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein","volume":"16","author":"Zsila","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_63","first-page":"622","article-title":"Cats inoculated with feline infectious peritonitis virus exhibit a biphasic acute phase plasma protein response","volume":"123","author":"Stoddart","year":"1988","journal-title":"Vet. Rec."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/vr.141.12.299","article-title":"Value of alpha 1-acid glycoprotein in the diagnosis of feline infectious peritonitis","volume":"141","author":"Duthie","year":"1997","journal-title":"Vet. Rec."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1090-0233(03)00055-8","article-title":"Changes in some acute phase protein and immunoglobulin concentrations in cats affected by feline infectious peritonitis or exposed to feline coronavirus infection","volume":"167","author":"Giordano","year":"2004","journal-title":"Vet. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/104063870701900306","article-title":"Critical assessment of the diagnostic value of feline alpha1-acid glycoprotein for feline infectious peritonitis using the likelihood ratios approach","volume":"19","author":"Paltrinieri","year":"2007","journal-title":"J. Vet. Diagn. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jvim.12445","article-title":"Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease","volume":"28","author":"Hall","year":"2014","journal-title":"J. Vet. Intern. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/jvim.12835","article-title":"Symmetric dimethylarginine assay validation, stability, and evaluation as a marker for the early detection of chronic kidney disease in dogs","volume":"29","author":"Nabity","year":"2015","journal-title":"J. Vet. Intern. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cvsm.2016.06.011","article-title":"Kidney disease and the nexus of chronic kidney disease and acute kidney injury: The role of novel biomarkers as early and accurate diagnostics","volume":"46","author":"Yerramilli","year":"2016","journal-title":"Vet. Clin. North. Am. Small Anim. Pract."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/jvim.14694","article-title":"Plasma symmetric dimethylarginine concentration in dogs with acute kidney injury and chronic kidney disease","volume":"31","author":"Dahlem","year":"2017","journal-title":"J. Vet. Intern. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/jvim.12446","article-title":"Relationship between serum symmetric dimethylarginine concentration and glomerular filtration rate in cats","volume":"28","author":"Braff","year":"2014","journal-title":"J. Vet. Intern. Med."},{"key":"ref_72","first-page":"11","article-title":"Antimalarial drug and renal toxicity","volume":"5","author":"Wiwanitkit","year":"2016","journal-title":"J. Nephropharmacol."},{"key":"ref_73","unstructured":"Namba, S., Kitamura, R., Amaha, T., Befu, M., Zama, T., Moriwaki, T., Kumono, S., and Shichijo, S. (2018, January 27\u201330). Impact of general anesthesia on serum symmetric dimethylarginine concentration in cats. Proceedings of the American Association of Feline Practitioners Conference 2018, Charlotte, NC, USA."}],"container-title":["Animals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2615\/10\/6\/1000\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:36:48Z","timestamp":1760175408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2615\/10\/6\/1000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":73,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["ani10061000"],"URL":"https:\/\/doi.org\/10.3390\/ani10061000","relation":{},"ISSN":["2076-2615"],"issn-type":[{"value":"2076-2615","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]}}}